-
Product Insights
Hip Reconstruction – Smith & Nephew Plc – SMF
GlobalData, the industry analysis specialist, has released its latest report: Hip Reconstruction - Smith & Nephew Plc - SMF. The selling price or list price of a medical device is driven by numerous factors, such as therapy area and complexity of procedure, level of reimbursement, development costs, the number of competing manufacturers, product life cycle, and whether there have been any recent new technology or product launches. In addition, the final selling pricing of medical devices is also impacted by...
-
Product Insights
Hip Reconstruction – Smith & Nephew Plc – SMF STIKTITE
GlobalData, the industry analysis specialist, has released its latest report: Hip Reconstruction - Smith & Nephew Plc - SMF STIKTITE. The selling price or list price of a medical device is driven by numerous factors, such as therapy area and complexity of procedure, level of reimbursement, development costs, the number of competing manufacturers, product life cycle, and whether there have been any recent new technology or product launches. In addition, the final selling pricing of medical devices is also impacted...
-
Sector Analysis
Myelofibrosis Epidemiology Analysis and Forecast, 2021-2031
In the 8MM, there were 69,236 diagnosed prevalent cases of Myelofibrosis (MF) in 2021. MF belongs to a group of diseases called myeloproliferative disorders. MF is a serious bone marrow disorder that disrupts the body’s normal production of blood cells (MedlinePlus, 2020; Mayo Clinic, 2021). MF includes primary MF (PMF), which is idiopathic. At times, essential thrombocytosis (ET) or polycythemia vera (PV) could progress to MF, resulting in post-essential thrombocytosis MF (PET MF) and post-polycythemia vera MF (PPV MF), which...
-
Sector Analysis
EpiCast Report: Myelofibrosis – Epidemiology Forecast to 2025
This report provides an overview of the risk factors, comorbidities, and the global and historical trends for myelofibrosis in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed incident and diagnosed prevalent cases of myelofibrosis, PMF, PET MF and PPV MF based on county-specific studies published in peer-reviewed journals. The diagnosed incident cases of PMF are further segmented by sex, age (40-49 years, 50-59 years, 60-69 years,...